Purpose: We previously showed that prostate-specific antigen (PSA) doubling time (PSADT) is a significant predictor of C-11 choline positron emission tomography/computed tomography (PET/CT) findings in prostate cancer (PCa) patients. This study compared PSA velocity (PSAV) and PSADT to predict C-11 choline PET/CT findings. Materials and Methods: PSAV and PSADT were retrospectively calculated in 170 PCa patients with biochemical failure after radical prostatectomy, who underwent C-11 choline PET/CT for restaging of disease. Results: Median PSA was 1.25 ng/mL (range: 0.23-48.6 ng/mL), and median PSAV was 0.99 ng/mL/y (range: 0.11-98.9 ng/mL/y). Patients with positive C-11 choline PET/CT (n = 75) had significantly (P < 0.05) higher PSAV than patients with negative C-11 choline PET/CT (n = 95) (6.93 +/- 13.08 vs. 1.23 +/- 2.03 ng/mL/y). The percent of patients with positive C-11 choline PET/CT was 21% for PSAV <1 ng/mL/y, 56% for PSAV between 1 and 2 ng/mL/y, and 76% for PSAV >2 ng/mL/y. The quality of fitting (r(2)) of PSA values according to the exponential function (PSADT) was significantly (P < 0.05) better than the quality of fitting according to the linear function (PSAV) in the entire sample and in all anatomic regions. At multivariate analysis, trigger PSA, PSADT but not PSAV obtained the statistical significance (P < 0.05). Conclusions: PSAV can be used to stratify the risk of positive C-11 choline PET/CT in PCa patients with biochemical failure. Patients with PSAV >1 ng/mL/y should be selected to increase the positive detection rate of C-11 choline PET/CT. The greater statistical power of PSADT compared with PSAV could be related to the better capability of fitting time-dependent changes in PSA values, thereby better reflecting the natural growth of recurrent PCa.

Purpose: We previously showed that prostate-specific antigen (PSA) doubling time (PSADT) is a significant predictor of C-11 choline positron emission tomography/computed tomography (PET/CT) findings in prostate cancer (PCa) patients. This study compared PSA velocity (PSAV) and PSADT to predict C-11 choline PET/CT findings. Materials and Methods: PSAV and PSADT were retrospectively calculated in 170 PCa patients with biochemical failure after radical prostatectomy, who underwent C-11 choline PET/CT for restaging of disease. Results: Median PSA was 1.25 ng/mL (range: 0.23-48.6 ng/mL), and median PSAV was 0.99 ng/mL/y (range: 0.11-98.9 ng/mL/y). Patients with positive C-11 choline PET/CT (n = 75) had significantly (P < 0.05) higher PSAV than patients with negative C-11 choline PET/CT (n = 95) (6.93 +/- 13.08 vs. 1.23 +/- 2.03 ng/mL/y). The percent of patients with positive C-11 choline PET/CT was 21% for PSAV <1 ng/mL/y, 56% for PSAV between 1 and 2 ng/mL/y, and 76% for PSAV >2 ng/mL/y. The quality of fitting (r(2)) of PSA values according to the exponential function (PSADT) was significantly (P < 0.05) better than the quality of fitting according to the linear function (PSAV) in the entire sample and in all anatomic regions. At multivariate analysis, trigger PSA, PSADT but not PSAV obtained the statistical significance (P < 0.05). Conclusions: PSAV can be used to stratify the risk of positive C-11 choline PET/CT in PCa patients with biochemical failure. Patients with PSAV >1 ng/mL/y should be selected to increase the positive detection rate of C-11 choline PET/CT. The greater statistical power of PSADT compared with PSAV could be related to the better capability of fitting time-dependent changes in PSA values, thereby better reflecting the natural growth of recurrent PCa.

Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy

Picchio Maria;Briganti Alberto;Montorsi F;
2012

Abstract

Purpose: We previously showed that prostate-specific antigen (PSA) doubling time (PSADT) is a significant predictor of C-11 choline positron emission tomography/computed tomography (PET/CT) findings in prostate cancer (PCa) patients. This study compared PSA velocity (PSAV) and PSADT to predict C-11 choline PET/CT findings. Materials and Methods: PSAV and PSADT were retrospectively calculated in 170 PCa patients with biochemical failure after radical prostatectomy, who underwent C-11 choline PET/CT for restaging of disease. Results: Median PSA was 1.25 ng/mL (range: 0.23-48.6 ng/mL), and median PSAV was 0.99 ng/mL/y (range: 0.11-98.9 ng/mL/y). Patients with positive C-11 choline PET/CT (n = 75) had significantly (P < 0.05) higher PSAV than patients with negative C-11 choline PET/CT (n = 95) (6.93 +/- 13.08 vs. 1.23 +/- 2.03 ng/mL/y). The percent of patients with positive C-11 choline PET/CT was 21% for PSAV <1 ng/mL/y, 56% for PSAV between 1 and 2 ng/mL/y, and 76% for PSAV >2 ng/mL/y. The quality of fitting (r(2)) of PSA values according to the exponential function (PSADT) was significantly (P < 0.05) better than the quality of fitting according to the linear function (PSAV) in the entire sample and in all anatomic regions. At multivariate analysis, trigger PSA, PSADT but not PSAV obtained the statistical significance (P < 0.05). Conclusions: PSAV can be used to stratify the risk of positive C-11 choline PET/CT in PCa patients with biochemical failure. Patients with PSAV >1 ng/mL/y should be selected to increase the positive detection rate of C-11 choline PET/CT. The greater statistical power of PSADT compared with PSAV could be related to the better capability of fitting time-dependent changes in PSA values, thereby better reflecting the natural growth of recurrent PCa.
Purpose: We previously showed that prostate-specific antigen (PSA) doubling time (PSADT) is a significant predictor of C-11 choline positron emission tomography/computed tomography (PET/CT) findings in prostate cancer (PCa) patients. This study compared PSA velocity (PSAV) and PSADT to predict C-11 choline PET/CT findings. Materials and Methods: PSAV and PSADT were retrospectively calculated in 170 PCa patients with biochemical failure after radical prostatectomy, who underwent C-11 choline PET/CT for restaging of disease. Results: Median PSA was 1.25 ng/mL (range: 0.23-48.6 ng/mL), and median PSAV was 0.99 ng/mL/y (range: 0.11-98.9 ng/mL/y). Patients with positive C-11 choline PET/CT (n = 75) had significantly (P &lt; 0.05) higher PSAV than patients with negative C-11 choline PET/CT (n = 95) (6.93 +/- 13.08 vs. 1.23 +/- 2.03 ng/mL/y). The percent of patients with positive C-11 choline PET/CT was 21% for PSAV &lt;1 ng/mL/y, 56% for PSAV between 1 and 2 ng/mL/y, and 76% for PSAV &gt;2 ng/mL/y. The quality of fitting (r(2)) of PSA values according to the exponential function (PSADT) was significantly (P &lt; 0.05) better than the quality of fitting according to the linear function (PSAV) in the entire sample and in all anatomic regions. At multivariate analysis, trigger PSA, PSADT but not PSAV obtained the statistical significance (P &lt; 0.05). Conclusions: PSAV can be used to stratify the risk of positive C-11 choline PET/CT in PCa patients with biochemical failure. Patients with PSAV &gt;1 ng/mL/y should be selected to increase the positive detection rate of C-11 choline PET/CT. The greater statistical power of PSADT compared with PSAV could be related to the better capability of fitting time-dependent changes in PSA values, thereby better reflecting the natural growth of recurrent PCa.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/7634
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 39
social impact